Skip to main content
Erschienen in: Journal of Gastrointestinal Surgery 12/2017

07.08.2017 | Original Article

Trends in the Mortality of Hepatocellular Carcinoma in the United States

verfasst von: Eliza W. Beal, Dmitry Tumin, Ali Kabir, Dimitrios Moris, Xu-Feng Zhang, Jeffery Chakedis, Kenneth Washburn, Sylvester Black, Carl M. Schmidt, Timothy M. Pawlik

Erschienen in: Journal of Gastrointestinal Surgery | Ausgabe 12/2017

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Primary liver cancer mortality rates have been increasing in the US, but reported decreases among 35–49 year olds may foreshadow future declines. We sought to use age-period-cohort (APC) modeling to evaluate the contribution of cohort effects to hepatocellular carcinoma (HCC) mortality trends in the US.

Methods

Data on HCC mortality were obtained from the Centers for Disease Control and Prevention National Center for Health Statistics WONDER Online Multiple Cause of Death database, 1999–2015. Crude mortality rates were plotted by gender and age at death. Gender-specific restricted cubic spline APC models were fit to determine influence of birth cohort on incidence of HCC mortality, in reference to the 1940 birth cohort.

Results

Highest mortality rates were found among men ages 70+, with steepest increase in mortality observed among men 55–69 years old. Similar trends were found among females. Accounting for the cohort effect in the APC model markedly improved model fit (likelihood ratio test p < 0.001). Relative to the 1940 birth cohort, risk of mortality due to HCC was significantly higher in later as well as earlier cohorts.

Conclusions

HCC-associated mortality continues to increase, secondary to an increase in the risk of HCC-associated mortality in more recent birth cohorts among both men and women.
Literatur
1.
Zurück zum Zitat Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65(2):87–108.CrossRefPubMed Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65(2):87–108.CrossRefPubMed
2.
Zurück zum Zitat Menahem B, Lubrano J, Duvoux C, Mulliri A, Alves A, Costentin C, et al. Liver transplantation versus liver resection for hepatocellular carcinoma in intention to treat: An attempt to perform an ideal meta-analysis. Liver Transpl. 2017; 23(6):836–844. doi:10.1002/lt.24758. Menahem B, Lubrano J, Duvoux C, Mulliri A, Alves A, Costentin C, et al. Liver transplantation versus liver resection for hepatocellular carcinoma in intention to treat: An attempt to perform an ideal meta-analysis. Liver Transpl. 2017; 23(6):836–844. doi:10.​1002/​lt.​24758.
3.
Zurück zum Zitat Murali AR, Patil S, Phillips KT, Voigt M. Locoregional therapy with curative intent versus primary liver transplant for hepatocellular carcinoma: systematic review and meta-analysis. Transplantation. 2017; 101(8):e249–e257. doi:10.1097/TP.0000000000001730. Murali AR, Patil S, Phillips KT, Voigt M. Locoregional therapy with curative intent versus primary liver transplant for hepatocellular carcinoma: systematic review and meta-analysis. Transplantation. 2017; 101(8):e249–e257. doi:10.​1097/​TP.​0000000000001730​.
4.
Zurück zum Zitat Alver SK, Lorenz DJ, Marvin MR, Brock GN. Projected outcomes of 6-month delay in exception points versus an equivalent Model for End-Stage Liver Disease score for hepatocellular carcinoma liver transplant candidates. Liver Transpl. 2016; 22 (10):1343–55.CrossRefPubMed Alver SK, Lorenz DJ, Marvin MR, Brock GN. Projected outcomes of 6-month delay in exception points versus an equivalent Model for End-Stage Liver Disease score for hepatocellular carcinoma liver transplant candidates. Liver Transpl. 2016; 22 (10):1343–55.CrossRefPubMed
5.
Zurück zum Zitat Alver SK, Lorenz DJ, Washburn K, Marvin MR, Brock GN. Comparison of two equivalent MELD scores for hepatocellular carcinoma patients using data from the United Network for Organ Sharing liver transplant waiting list registry. Transpl Int. 2017. doi:10.1111/tri.12967. Alver SK, Lorenz DJ, Washburn K, Marvin MR, Brock GN. Comparison of two equivalent MELD scores for hepatocellular carcinoma patients using data from the United Network for Organ Sharing liver transplant waiting list registry. Transpl Int. 2017. doi:10.​1111/​tri.​12967.
6.
Zurück zum Zitat Ioannou GN. Transplant-related survival benefit should influence prioritization for liver transplantation especially in patients with hepatocellular carcinoma. Liver Transpl. 2017; 23(5):652–62.CrossRefPubMed Ioannou GN. Transplant-related survival benefit should influence prioritization for liver transplantation especially in patients with hepatocellular carcinoma. Liver Transpl. 2017; 23(5):652–62.CrossRefPubMed
7.
Zurück zum Zitat Rich NE, Parikh ND, Singal AG. Hepatocellular Carcinoma and Liver Transplantation: Changing Patterns and Practices. Curr Treat Options Gastroenterol. 2017; 15(2):296–304. doi:10.1007/s11938-017-0133-3. Rich NE, Parikh ND, Singal AG. Hepatocellular Carcinoma and Liver Transplantation: Changing Patterns and Practices. Curr Treat Options Gastroenterol. 2017; 15(2):296–304. doi:10.​1007/​s11938-017-0133-3.
11.
Zurück zum Zitat Altekruse SF, Henley SJ, Cucinelli JE, McGlynn KA. Changing hepatocellular carcinoma incidence and liver cancer mortality rates in the United States. Am J Gastroenterol. 2014; 109(4):542–53.CrossRefPubMedPubMedCentral Altekruse SF, Henley SJ, Cucinelli JE, McGlynn KA. Changing hepatocellular carcinoma incidence and liver cancer mortality rates in the United States. Am J Gastroenterol. 2014; 109(4):542–53.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Park J, Jee YH. Age-Period-Cohort Analysis of Liver Cancer Mortality in Korea. Asian Pac J Cancer Prev. 2015; 16 (18):8589–94.CrossRefPubMed Park J, Jee YH. Age-Period-Cohort Analysis of Liver Cancer Mortality in Korea. Asian Pac J Cancer Prev. 2015; 16 (18):8589–94.CrossRefPubMed
13.
Zurück zum Zitat Tzeng IS, Lee WC. Forecasting hepatocellular carcinoma mortality in Taiwan using an age-period-cohort model. Asia Pac J Public Health. 2015; 27(2):NP65–73.CrossRefPubMed Tzeng IS, Lee WC. Forecasting hepatocellular carcinoma mortality in Taiwan using an age-period-cohort model. Asia Pac J Public Health. 2015; 27(2):NP65–73.CrossRefPubMed
14.
Zurück zum Zitat Akita T, Ohisa M, Kimura Y, Fujimoto M, Miyakawa Y, Tanaka J. Validation and limitation of age-period-cohort model in simulating mortality due to hepatocellular carcinoma from 1940 to 2010 in Japan. Hepatol Res. 2014; 44(7):713–9.CrossRefPubMed Akita T, Ohisa M, Kimura Y, Fujimoto M, Miyakawa Y, Tanaka J. Validation and limitation of age-period-cohort model in simulating mortality due to hepatocellular carcinoma from 1940 to 2010 in Japan. Hepatol Res. 2014; 44(7):713–9.CrossRefPubMed
15.
Zurück zum Zitat Bertuccio P, Turati F, Carioli G, Rodriguez T, La Vecchia C, Malvezzi M, et al. Global trends and predictions in hepatocellular carcinoma mortality. J Hepatol. 2017. Bertuccio P, Turati F, Carioli G, Rodriguez T, La Vecchia C, Malvezzi M, et al. Global trends and predictions in hepatocellular carcinoma mortality. J Hepatol. 2017.
16.
Zurück zum Zitat Statistics. C-NCfDCaPNCfH. Multiple Cause of Death 1999–2015 on CDC WONDER Online Database, Released December 2016. Statistics. C-NCfDCaPNCfH. Multiple Cause of Death 1999–2015 on CDC WONDER Online Database, Released December 2016.
17.
Zurück zum Zitat Carstensen B. Age-period-cohort models for the Lexis diagram. Stat Med. 2007; 26 (15):3018–45.CrossRefPubMed Carstensen B. Age-period-cohort models for the Lexis diagram. Stat Med. 2007; 26 (15):3018–45.CrossRefPubMed
18.
Zurück zum Zitat Rutherford MJ, Lambert PC, Thompson JR. Age–period–cohort modeling. The Stata Journal. 2010; 10(4):606–27. Rutherford MJ, Lambert PC, Thompson JR. Age–period–cohort modeling. The Stata Journal. 2010; 10(4):606–27.
19.
Zurück zum Zitat Durrleman S, Simon R. Flexible regression models with cubic splines. Stat Med. 1989; 8(5):551–61.CrossRefPubMed Durrleman S, Simon R. Flexible regression models with cubic splines. Stat Med. 1989; 8(5):551–61.CrossRefPubMed
20.
Zurück zum Zitat White DL, Thrift AP, Kanwal F, Davila J, El-Serag HB. Incidence of Hepatocellular Carcinoma in All 50 United States, From 2000 Through 2012. Gastroenterology. 2017; 152(4):812–20.e5.CrossRefPubMed White DL, Thrift AP, Kanwal F, Davila J, El-Serag HB. Incidence of Hepatocellular Carcinoma in All 50 United States, From 2000 Through 2012. Gastroenterology. 2017; 152(4):812–20.e5.CrossRefPubMed
21.
Zurück zum Zitat Yang JD, Kim WR, Coelho R, Mettler TA, Benson JT, Sanderson SO, et al. Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2011; 9(1):64–70.CrossRefPubMed Yang JD, Kim WR, Coelho R, Mettler TA, Benson JT, Sanderson SO, et al. Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2011; 9(1):64–70.CrossRefPubMed
22.
Zurück zum Zitat Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004; 127 (5 Suppl 1):S35–50.CrossRefPubMed Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004; 127 (5 Suppl 1):S35–50.CrossRefPubMed
23.
Zurück zum Zitat Asselah T, Boyer N, Saadoun D, Martinot-Peignoux M, Marcellin P. Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives. Liver Int. 2016; 36 Suppl 1:47–57.CrossRefPubMed Asselah T, Boyer N, Saadoun D, Martinot-Peignoux M, Marcellin P. Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives. Liver Int. 2016; 36 Suppl 1:47–57.CrossRefPubMed
24.
Zurück zum Zitat El-Serag HB, Kanwal F. Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go? Hepatology. 2014; 60(5):1767–75.CrossRefPubMedPubMedCentral El-Serag HB, Kanwal F. Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go? Hepatology. 2014; 60(5):1767–75.CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Wong RJ, Aguilar M, Cheung R, Perumpail RB, Harrison SA, Younossi ZM, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015; 148(3):547–55.CrossRefPubMed Wong RJ, Aguilar M, Cheung R, Perumpail RB, Harrison SA, Younossi ZM, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015; 148(3):547–55.CrossRefPubMed
28.
Zurück zum Zitat Unzueta A, Cabrera R. Treatment Options in Patients Awaiting Liver Transplantation with Hepatocellular Carcinoma and Cholangiocarcinoma. Clin Liver Dis. 2017;21(2):231–51.CrossRefPubMed Unzueta A, Cabrera R. Treatment Options in Patients Awaiting Liver Transplantation with Hepatocellular Carcinoma and Cholangiocarcinoma. Clin Liver Dis. 2017;21(2):231–51.CrossRefPubMed
29.
Zurück zum Zitat Gavriilidis P, Askari A, Azoulay D. Survival following redo hepatectomy vs radiofrequency ablation for recurrent hepatocellular carcinoma: a systematic review and meta-analysis. HPB (Oxford). 2017; 19(1):3–9.CrossRefPubMed Gavriilidis P, Askari A, Azoulay D. Survival following redo hepatectomy vs radiofrequency ablation for recurrent hepatocellular carcinoma: a systematic review and meta-analysis. HPB (Oxford). 2017; 19(1):3–9.CrossRefPubMed
Metadaten
Titel
Trends in the Mortality of Hepatocellular Carcinoma in the United States
verfasst von
Eliza W. Beal
Dmitry Tumin
Ali Kabir
Dimitrios Moris
Xu-Feng Zhang
Jeffery Chakedis
Kenneth Washburn
Sylvester Black
Carl M. Schmidt
Timothy M. Pawlik
Publikationsdatum
07.08.2017
Verlag
Springer US
Erschienen in
Journal of Gastrointestinal Surgery / Ausgabe 12/2017
Print ISSN: 1091-255X
Elektronische ISSN: 1873-4626
DOI
https://doi.org/10.1007/s11605-017-3526-7

Weitere Artikel der Ausgabe 12/2017

Journal of Gastrointestinal Surgery 12/2017 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.